Drugs / Ligufalimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06789848 | Feb 2025 → May 2029 expected | biliary tract cancer, hepatocellular carcinoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07264075 | May 2026 → May 2030 expected | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | Akeso | CD47单抗（AK117）联合PD-1/VEGF双抗（AK112）联合或不联合化疗治疗恶性肿瘤的Ib/II临床研究获批开展 akesobio.com ↗ |
| 2021-12-24 | Akeso | 康方生物发布CD47单抗（AK117）药物机制研究成果 akesobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ligufalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789848 ↗ |
| Known as | AK117 | “Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks” NCT06789848 ↗ |
| Route | Intravenous | “Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks” NCT06789848 ↗ |